Corbus Pharmaceuticals (CRBP) director Alan Holmer resigns from board to retire

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. announced that long-time board member Alan Holmer has decided to retire from its Board of Directors. He notified the company of his resignation on December 12, 2025, and his service will end effective December 31, 2025. The company states that his decision to step down is due to retirement and is not the result of any disagreement with management or with the company’s operations, policies, or practices. This indicates an orderly governance transition rather than a conflict-driven departure.

0001595097false00015950972025-12-122025-12-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37348	46-4348039
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
500 River Ridge Drive
Norwood, Massachusetts				02062
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CRBP		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 12, 2025, Alan Holmer provided Corbus Pharmaceuticals Holdings, Inc. (the “Company”) with notice of his resignation from the Board of Directors, effective December 31, 2025, due to retirement. Mr. Holmer’s decision to resign was not the result of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Corbus Pharmaceuticals Holdings, Inc.
Date:	December 18, 2025	By:	/s/ Yuval Cohen
			Name: Yuval Cohen Title: Chief Executive Officer

FAQ

What did Corbus Pharmaceuticals (CRBP) disclose about its board changes?

Corbus Pharmaceuticals disclosed that Alan HolmerDecember 12, 2025, and his resignation becomes effective on December 31, 2025.

Why is Corbus Pharmaceuticals (CRBP) director Alan Holmer resigning?

The company states that Alan Holmer is resigning from the Board of Directors due to retirement, indicating a planned transition rather than an abrupt departure.

Did Alan Holmer have any disagreements with Corbus Pharmaceuticals (CRBP) before resigning?

No. Corbus Pharmaceuticals states that Mr. Holmer’s decision to resign was not the result of any disagreement with the company or its management on operations, policies, or practices.

When does the director resignation at Corbus Pharmaceuticals (CRBP) take effect?

Alan Holmer’s resignation from the Board of Directors is effective December 31, 2025, following his notice given on December 12, 2025.

Does the Corbus Pharmaceuticals (CRBP) board change signal any operational issues?

Based on the company’s disclosure, Mr. Holmer’s departure is due to retirement and not due to disagreements over the company’s operations, policies, or practices.

Who signed the recent disclosure for Corbus Pharmaceuticals (CRBP)?

The disclosure was signed on behalf of Corbus Pharmaceuticals by Yuval Cohen, who is identified as the company’s Chief Executive Officer.